Q-omics provides the consensus-scored ZBTB8OSP1 profile across patient tissues and cancer cell-line models. ZBTB8OSP1 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, ZBTB8OSP1 is differentially expressed in 4, with the highest sampling consensus in HNSC. Additionally, ZBTB8OSP1 RNA expression shows 6,465 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight KIRP, HNSC, and LUAD as cancer lineages where ZBTB8OSP1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZBTB8OSP1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZBTB8OSP1 survival associations across molecular data types. ZBTB8OSP1 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZBTB8OSP1 RNA expression–survival associations across cancer types. High ZBTB8OSP1 expression shows unfavorable associations in TGCT, THCA, HNSC and ESCA, but favorable associations in KIRP and BRCA. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .006). Together, the overview and detailed table identify KIRP as the clearest survival context for ZBTB8OSP1 RNA expression.
This table summarizes ZBTB8OSP1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ZBTB8OSP1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZBTB8OSP1 shows higher tumor expression in HNSC, COAD, BRCA and LUSC. The HNSC box plot shows higher ZBTB8OSP1 RNA expression in tumor versus normal tissue (log2 FC = +0.035, t-test p = .019).
This table shows molecular features associated with ZBTB8OSP1 in patient tissues and cancer cell lines. In patient samples, ZBTB8OSP1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set.
